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West	Nile	virus	(WNV)	causes	asymptomatic	infection	in	most	humans,	but	for	undefined	reasons,	approxi-
mately	20%	of	immunocompetent	individuals	develop	West	Nile	fever,	a	potentially	debilitating	febrile	illness,	
and	approximately	1%	develop	neuroinvasive	disease	syndromes.	Notably,	since	its	emergence	in	1999,	WNV	
has	become	the	leading	cause	of	epidemic	viral	encephalitis	in	North	America.	We	hypothesized	that	CD4+	
Tregs	might	be	differentially	regulated	in	subjects	with	symptomatic	compared	with	those	with	asymptomatic	
WNV	infection.	Here,	we	show	that	in	32	blood	donors	with	acute	WNV	infection,	Tregs	expanded	signifi-
cantly	in	the	3	months	after	index	(RNA+)	donations	in	all	subjects.	Symptomatic	donors	exhibited	lower	Treg	
frequencies	from	2	weeks	through	1	year	after	index	donation	yet	did	not	show	differences	in	systemic	T	cell	or	
generalized	inflammatory	responses.	In	parallel	prospective	experimental	studies,	symptomatic	WNV-infected	
mice	also	developed	lower	Treg	frequencies	compared	with	asymptomatic	mice	at	2	weeks	after	infection.	
Moreover,	Treg-deficient	mice	developed	lethal	WNV	infection	at	a	higher	rate	than	controls.	Together,	these	
results	suggest	that	higher	levels	of	peripheral	Tregs	after	infection	protect	against	severe	WNV	disease	in	
immunocompetent	animals	and	humans.
Introduction
West Nile virus (WNV), an encephalitic positive polarity RNA virus 
of the Flaviviridae family, was first isolated in 1937 in the West Nile 
district of Uganda from the blood of a febrile woman (1). It entered 
North America in 1999 and spread rapidly across the United States 
and Canada, and nearly 29,000 symptomatic infections including 
fever, meningitis, and/or encephalitis and over 1100 deaths have 
been reported by the CDC (2). Based on blood supply screening 
and seroprevalence testing, recent estimates suggest that approxi-
mately 2 million people have been infected during the epidemic, 
most with clinically unapparent cases (3).
Considerable progress in understanding the kinetics and mech-
anisms of viral dissemination and pathogenesis has been made 
studying WNV infection in rodent models (4). Innate immune 
responses, interferon secretion (5, 6), complement activation (7), 
and cellular innate immunity (8, 9) function to limit the spread 
and replication of WNV. Studies on the humoral response have 
established that neutralizing antibodies (10) are also protective 
(11). T cell responses also contribute to viral clearance (12, 13), 
as release of proinflammatory cytokines and antigen-restricted 
CTL responses are seen in mice (14) and humans (15), with perfo-
rin and granzymes required for WNV clearance from the CNS of 
infected mice (16, 17). While an intact immune response is clearly 
key to control of WNV infection (18), an overexuberant immune 
response may also contribute to disease (19, 20).
CD4+ Tregs are able to suppress effector T cells to prevent or 
control reactivity to self antigens (21) and pathogens (22), to 
blunt inflammation (23), and to maintain antigen-specific T cell 
homeostasis (24). Multiple Treg populations have been report-
ed (25), with naturally occurring Tregs the most widely studied 
and best characterized (26). Natural Tregs constitutively express 
molecules such as CD25 (IL-2 receptor α-chain) (27), cytotoxic T 
lymphocyte–associated antigen 4 (CTLA-4 or CD152) (28), and 
glucocorticoid-induced TNF receptor (GITR) (29), also expressed 
by nonregulatory T cells after activation. More specifically, Tregs 
express the forkhead/winged helix transcription factor gene fork-
head box P3 (Foxp3), described as a key control gene in their devel-
opment and function (30). More recent studies demonstrate that 
Tregs also express low levels of CD127 (31, 32). While no single 
marker uniquely identifies Treg populations, panels of markers 
allow identification of CD4+ T cells with suppressive activity.
In the present study, we explored the hypothesis that Treg levels 
in individuals with WNV infection associate with disease outcome. 
Serial samples were collected from a cohort of WNV+ blood donors, 
identified through routine screening for WNV RNA in blood dona-
tions. The presence or absence of WNV fever was determined using 
questionnaires, and effector immune responses and Treg levels were 
followed for 1 year after infection. Donors who developed symptom-
atic WNV infection possessed lower Treg levels at each point mea-
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sured after infection, even when Treg levels had returned to baseline 
1 year after infection. Parallel prospective studies in a mouse model 
of WNV infection confirmed the observations in humans.
Results
Study cohort characteristics. From over 800,000 United Blood Services 
donations screened for WNV in 2005, plasma from 45 donors test-
ed positive for WNV RNA. Thirty-two of these WNV+ donors were 
entered in this study and completed 2 symptom questionnaires 
administered at enrollment and 2 weeks after index donation. 
Validation of the questionnaires using donors with acute WNV 
or an initial false-positive WNV test revealed that of 12 possible 
symptoms (see Methods), the presence of 4 or more symptoms 
was associated with true WNV infection (odds ratio 3.28; 95% CI, 
1.71–6.28) (33). Given that up to 3 symptoms were found in non-
infected donors, this cutoff was used to designate WNV+ donors as 
asymptomatic (<4 symptoms) or symptomatic (≥4 symptoms). The 
most frequent symptom reported by the asymptomatic population 
was new skin rash (17% of asymptomatic), while the symptomatic 
populations most frequently reported body aches, headache, and 
weakness (88%, 76%, and 65%, respectively for symptomatic), then 
fever or eye pain (53% each). Most of the donors (81%) were enrolled 
while still in a very early phase of infection (WNV RNA+, IgM–IgG–; 
Table 1), and all seroconverted within 43 days of donation.
Identification of CD4+CD25hi Tregs. Tregs express several mark-
ers, such as CD25 (27), Foxp3 (30), GITR (29), and CTLA-4 (28), 
yet lack expression of CD127 (34) and are commonly defined as 
CD4+CD25hiFoxp3+ T cells. To validate our Treg-gating analy-
Table 1
Subject characteristics
Donor	 Age	 Sex	 Residence		 Before	 		 Index	donation	 	 	 After	donation	 	 	 Peak
	 	 	 state	 donation	 	 	 	 	 	 	 	 symptom	
	 	 	 	 	 	 	 	 	 	 	 	 numberB
	 	 	 	 Symptom		 IgM	 IgG	 Symptom		 After	 IgM	 IgG	 Symptom		
	 	 	 	 number	 	 	 number	 index	(d)A	 	 	 number
Asymptomatic	≤3
9860C 73 F Arizona 2 – – 0 7 – – 0 2
650 44 F New Mexico 0 – – 0 10 + + ND 0
1150 50 F New Mexico 0 – – 0 12 + + 0 0
1650 43 F North Dakota 0 – – 0 20 + + 0 0
1950 24 M New Mexico 0 – – 0 14 + + 0 0
2350 52 M Arizona 0 – – 0 19 + + 0 0
2450 73 F Arizona 0 – – 0 18 + + 0 0
2950 25 F Mississippi 0 – – 0 28 + + ND 0
3550 57 F Arkansas 0 – – 0 17 + + 0 0
350 60 F California 0 – – 0 12 + – 1 1
750 46 F Texas 1 – – 0 8 + – 0 1
950 55 F Nevada 0 – – 0 10 + + 2 2
550 45 F South Dakota 0 – – 2 13 + + 3 3
2550 39 F Arizona 3 – – 0 12 + + 0 3
1250 75 F South Dakota 0 + – 0 20 + + 0 0
250 36 F South Dakota 2 + – 0 12 + + 1 2
1450 38 F Texas 0 + + 0 15 + + 1 1
3050 59 F Mississippi 2 + + 0 13 + + 0 2
Symptomatic	≥4
450 47 F South Dakota 0 – – 0 10 + + 5 5
2650 46 M Arizona 0 – – 1 15 + + 5 5
1850 49 M Arizona 0 – – 2 12 + – 5 5
150 51 M Mississippi 3 – – 0 15 + + 5 5
2250D 39 F Mississippi 1 – + 0 12 + + 4 4
1750 50 F Minnesota 5 + – 0 15 + + 2 5
2850 31 F Arizona 0 – – 4 22 + + 5 5
1050 54 M North Dakota 4 – – 4 10 + + 2 4
3150 25 F South Dakota 7 – – 0 25 + + 4 7
3350 38 M Texas 3 – – 2 43 + + 8 8
1350 72 F South Dakota 9 – – 3 14 + + 4 9
2050 52 F North Dakota 4 – – 5 12 + + 8 8
850 26 F California 5 – – 1 15 + + 12 12
1550 47 M Minnesota 5 + + 2 15 + + 5 5
ADays between index blood donation and the first study visit, the first sample from which PBMCs and plasma could be isolated. BHighest number of symp-
toms reported on either questionnaire. CDonor 9860 seroconverted at day 12 after index donation. DDonor 2250 showed negative WNV plaque-reduction 
neutralization test at day 10, with titers rising to 1:5120 at day 16. ND, not done.
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sis, normal donor PBMCs were stained for CD3, CD4, CD25, 
CD152, CD127, and Foxp3. Live CD3+CD4+ cells were gated for 
analysis, with further gating on Foxp3+CD25+ cells. The gated 
CD3+CD4+CD25+Foxp3+ cells were primarily CD152+CD127– 
(Figure 1A). As described by others (31), the CD4+ T cells with the 
highest expression of CD25 constitutively expressed intracellular 
CTLA-4/CD152 and had low levels of CD127 (Figure 1B). In addi-
tion, CD25hiCD152+CD127– T cells expressed more Foxp3 than 
CD25int or CD25lo populations (Foxp3 mean linear fluorescence 
intensity = 518, 345, and 282, respectively; Figure 1C). Conversely, 
CD4+CD25hiFoxp3+ T cells fell in the CD127–/CD152+ gate. Tregs 
were defined as CD4+CD25hiCD152+CD127–.
Phenotypic study of CD4+CD25hiCD152+CD127– Tregs. CD4+CD25+ 
and CD4+CD25neg/int T cell populations were purified from PBMCs 
Figure 1
Identification of Tregs. PBMCs were stained ex vivo for CD3, CD4, CD25, Foxp3, CD152, and CD127. Lymphocytes were gated and dead cells 
excluded. (A) The Foxp3 cell gate was set to exclude Foxp3– and CD25– events within CD3+CD4+ cell populations. CD152+CD127– events were 
measured in CD25+Foxp3+lo (52%) and CD25+Foxp3+hi cells (95%) and in (B) CD25neg (4%), CD25int (5%), and CD25hi cells (63%). Levels of 
CD152, CD127, and Foxp3 staining were measured in CD25neg, CD25int, and CD25hi populations using selected gates. (C) CD25hi cells were 
68.9% CD152+, 14.3% CD127–, and 80.7% Foxp3+, compared with respective values of 13.2%, 89.9%, and 3.7% for CD25int cells and 8.6%, 
79.8%, and 0.6% for CD25neg cells. Results are from 1 representative of 3 normal human controls tested in 4 independent experiments. (D) 
Agarose gel with DNA stained with ethidium bromide. Expression of Foxp3 in CD4+CD25+ T cells compared with PBMCs or CD4+CD25– T cells, 
normalized for RNA input using β-actin primers (gel representative of 3 different experiments).
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by magnetic bead separation. Flow cytometric analysis demonstrat-
ed enrichment of CD152+CD127–Foxp3+ T cells in the CD4+CD25+ 
population compared with the CD25-depleted population (data 
not shown). The enrichment in Foxp3-expressing cells was also 
shown at the transcriptional level by RT-PCR (Figure 1D). To test 
the functional activity of the cells we identified as Tregs, the isolated 
CD4+CD25+ T cell fraction enriched in CD25hiCD152+CD127– cells 
(Figure 2A) was added back to CD25–CD4+ T cells stained with 
CFSE, and cultures were incubated for 4 days in the presence of stim-
ulatory anti-CD3/CD28 antibodies. As anticipated, CD4+CD25hi 
cells inhibited the proliferation of CD4+CD25– T cells (Figure 2B). 
Tregs from WNV-infected and healthy donors were equally effec-
tive at inhibiting proliferation at ratios of responder/Tregs of 
1:1, 2:1, or 4:1 (Figure 2C). These experiments confirmed that the 
CD4+CD25hiCD152+CD127– gate identified functional Tregs.
Treg frequency increases following acute WNV infection. Mean 
CD4+CD25+CD127lo or Treg frequencies in the 32 WNV+ donors 
were compared with those of 17 normal controls. Treg frequencies 
in WNV+ donors increased from 1.47% at 18 days after index dona-
tion to 2.62% at 90 days after index donation, with a significant 
increase compared with WNV– donors from 30 days (P < 0.01) to 
90 days after index donation (P < 0.0001) (Figure 3). By 1 year, 
postindex donation Treg frequencies had returned to a presumed 
baseline, which was indistinguishable from that of normal donors 
(1.33% and 1.24%, respectively, P = 0.52). These data demonstrate 
that Tregs expand continuously in humans during and after WNV 
Figure 2
Suppressive capacity of Tregs. (A) Comparison of CD25, CD127, and CD152 expression within CD4+ T cell fractions before magnetic bead 
separation (left panels) and after separation within Treg-depleted PBMCs (middle panels) and purified Tregs (right panels) from a normal human 
control. (B) CD25-depleted CD4+ T cells from a normal control and a representative WNV+ donor were stained with CFSE (CFSE+, right peak 
and middle population). After 4 days of incubation alone, with anti-CD3/CD28, or with anti-CD3/CD28 plus Tregs (CFSE–, left peak), proliferation 
was analyzed after staining for CD4 and propidium iodide. Tregs were not stained and appear at the far left of the plot. Dot plots are shown for 
1 representative WNV– donor. (C) Bar diagrams are representative of 3 WNV– and 3 WNV+ donors, with samples collected 30 days after index 
donation for the WNV+ donors. Treg suppression of anti-CD3/CD28–induced proliferation at 4 days is shown at varied effector to Treg ratios, 
averaging experiments from 3 WNV– and WNV+ donors (error bars represent SEM).
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for 2 to 3 months after index donation and contract back to a base-
line level by 1 year after index donation.
Symptomatic subjects exhibit lower Treg levels than asymptomatic subjects. 
We hypothesized that higher Treg frequency might correlate with 
less symptomatic WNV infection. While Tregs might be expected 
to impede clearance of a potentially chronic infection (35, 36), 
their presence also could ameliorate symptoms caused by “collat-
eral damage” of the immune response to an acute viral infection. 
Indeed, symptomatic donors had lower frequencies of Tregs than 
asymptomatic donors from the earliest time point tested through 
resolution of infection (P = 0.02 at <18 days, P = 0.04 at 60 days, 
P = 0.06 at 365 days after index donation; Figure 4). Analysis using 
generalized estimating equations showed that Treg frequency was 
41% lower (95% CI, 13%–60%, P = 0.008) in symptomatic compared 
with asymptomatic donors across all time periods. Although Treg 
frequency has been reported to increase with age (37) and non-
neuroinvasive yet symptomatic WNV fever is more common in 
younger subjects (38), we observed no significant difference in the 
mean age of asymptomatic and symptomatic donors in our cohort 
(asymptomatic = 48.5 and symptomatic = 44.8 years, P = 0.44 for 
asymptomatic vs. symptomatic; Figure 5A) and only a weak corre-
lation between Treg frequency and age (r2 = 0.19; Figure 5B).
Lower Treg levels are observed in symptomatic versus asymptomatic 
WNV-infected mice. Because preinfection samples were not available 
for the human studies, it was impossible to evaluate whether the 
difference in Treg frequencies between symptomatic and asymp-
tomatic subjects predated WNV infection or whether these differ-
ences developed during the first 2 weeks of infection, prior to the 
first Treg measurement. To test this hypothesis, we compared Treg 
values with WNV disease outcome phenotypes after infection of 
C57BL/6 mice. Mice were infected with a low inoculum (1 PFU) of a 
virulent North American WNV strain and followed daily for changes 
in body weight, appearance, and activity. A group of 20 mice were 
euthanized at day 8 after infection, and levels of infectious WNV 
were quantified in the brain and spinal cord. Symptomatic mice 
(hunchback posture and fur ruffling) showed a concordance among 
clinical appearance (Figure 6A), weight loss, viral titer in the spinal 
cord and the brain at day 8 (Figure 6, B–D), and mortality. Another 
group of 40 mice was followed prospectively, with blood collected 
preinfection and at days 14 and 28 after infection. At 28 days after 
infection, the survival rate was 43% (Figure 6E), consistent with 
prior studies (39). Tregs were defined as CD4+CD25+CD152+Foxp3+ 
cells (Figure 6F). Unlike in humans, Treg levels decreased in symp-
tomatic mice that succumbed to WNV infection (Figure 6G). 
While the mice that died within 28 days of infection had slightly 
lower preinfection Treg frequencies than those that survived, 
the difference was not statistically significant (died = 4.10%, 
survived = 5.43% at day 7, P = 0.3). Lower levels of Tregs were 
observed in blood at day 14 after infection in mice that ultimately 
succumbed (died = 2.93%, survived = 5.80% at day 14, P = 0.004; 
Figure 6G). The finding of lower Treg levels at day 14 in mice that 
ultimately succumbed to infection was analogous to the findings of 
lower Treg levels in symptomatic humans. Interestingly, an inverse 
correlation between the level of Tregs and the level of WNV-specific 
CD8+ T cells was found at day 8 after infection, with animals exhib-
Figure 3
Increased Treg frequencies after WNV infection. Live CD3+CD4+ lymphocytes were gated on CD25+CD127loCD152+ (shaded area, Tregs). 
Evolution of Treg frequencies expressed as percentage of CD3+ T cells in 17 healthy WNV– donors and in 32 WNV+ donors at 5 time points after 
index donation. Twenty-one samples were available for the greater than 18 days time point, 30 at 30 days after index donation, 20 at 60 and 90 
days after index donation, 17 at 365 days after index donation. **P < 0.01; ***P < 0.0001.
Figure 4
Symptomatic WNV+ donors exhibit lower frequencies of Tregs. Evolu-
tion of Treg frequencies in 18 asymptomatic (AS) and 14 symptomatic 
(S) WNV+ donors at 5 time points after index donation. The average 
Treg frequency in the 17 WNV– donors at a single time point is repre-
sented by the dotted line. A minimum of 50,000 events were collected 
in the lymphocyte gate. Error bars represent SEM.
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iting lower WNV-specific CD8+ T cell responses having higher Treg 
levels (P = 0.012; Figure 6H), suggesting a possible protective effect 
of Tregs through dampening of WNV-specific immune responses. 
Although the WNV infection in mice recapitulates many features of 
human disease (4), the frequency of severe infection and kinetics of 
viral dissemination differ between the 2 models, likely accounting 
for some of the observed disparity in Treg dynamics.
Increased lethality following WNV infection in mice lacking Foxp3+ Tregs. 
To confirm the effect of Tregs on WNV infection and disease, we took 
advantage of Foxp3DTR knockin mice; in these animals Tregs express 
a diphtheria toxin receptor (DTR) on their cell surface. Treatment 
of Foxp3DTR mice with diphtheria toxin specifically and completely 
depletes the CD4+CD25+Foxp3+ cells (40, 41). Foxp3DTR mice that 
were treated with DT at day –1 and day 0 relative to infection with 
WNV showed more frequent and severe symptoms and weight loss 
(P < 0.01 and P = 0.02, respectively; Figure 7A), resulting in signifi-
cantly higher mortality rates (93%) compared with DT-treated or 
untreated WT mice or untreated Foxp3DTR mice that were infected 
with WNV (50%, 46%, and 44% mortality, respectively, P = 0.026; Fig-
ure 7B). Thus, an absence of Tregs at the earliest stage of WNV infec-
tion is detrimental to disease outcome in the mouse model.
Adaptive and innate immune mediators in WNV+ donors. One pos-
sible explanation for the increased Treg frequency in asymptom-
atic compared with symptomatic human subjects was that these 
were driven by higher-magnitude effector T cell responses and/or 
higher proinflammatory cytokines. To address this, IFN-γ produc-
tion from PBMCs stimulated with 18 amino acid peptides over-
lapping by 11 residues spanning the entire WNV proteome was 
quantified by ELISPOT (15). Notably, there was no significant dif-
ference between asymptomatic and symptomatic donors in terms 
of the median number of WNV peptides recognized (asymptom-
atic = 1, symptomatic = 1.5 peptides, P = 0.3) or the magnitude of 
response (asymptomatic = 75, symptomatic = 120 spot-forming 
cells [SFCs]/106 PBMCs, P = 0.2), though the proportion of donors 
making no detectable T cell response to WNV trended higher in 
the asymptomatic group (P = 0.06; Figure 8, A and B). As previ-
ously demonstrated (42), most WNV+ donors seroconverted by 
20 days after index donation, with a rapid and transient IgM 
response and sustained IgG levels (Figure 8C). Again, no signifi-
cant differences were observed in the kinetics or magnitude of 
WNV-specific IgM or IgG responses (P = 0.6 for IgM and P = 0.7 
for IgG) between symptomatic and asymptomatic individuals.
Tregs have complex interactions with cytokine networks that 
regulate their generation, expansion, and suppressor activity. 
Functionally important Treg-related cytokines include IL-2 (34), 
IL-10 (43), IL-6 (44), and TGF-β (45). To determine whether differ-
ences in Treg levels correlated with differences in systemic cytokine 
profiles, 11 asymptomatic and 8 symptomatic WNV+ donors 
(selected based only on specimen availability) were screened for 
cytokine and chemokine signatures at 5 different time points after 
index donation, but no significant differences in plasma cytokines 
or chemokines between asymptomatic and symptomatic WNV-
infected donors were observed (Figure 8D).
Discussion
We describe, for what we believe is the first time, a longitudinal 
study of Treg frequencies in WNV infection, made possible by 
screening a large population of healthy blood donors for viral RNA 
in plasma. Use of questionnaires allowed stratification of the study 
population into symptomatic and asymptomatic groups. Tregs 
were defined as CD3+CD4+CD25hiCD152+CD127– and shown to 
express Foxp3 and suppress proliferation. Somewhat surprisingly, 
Treg levels nearly doubled in the 3 months after infection in spite 
of only a transient viremia in the study subjects, though potential 
reservoir sites such as the spleen (39) and kidney (46) were not test-
ed for viral persistence. The major finding of this study was that, 
compared with asymptomatic donors, those with symptomatic 
infection had lower Treg frequencies throughout WNV infection 
and this difference persisted even 1 year after index donation when 
Treg levels had fallen to a presumed baseline level. To our knowl-
edge, this study shows the strongest correlation of Treg levels with 
infectious disease outcome in humans reported to date (47).
Risk factors associated with severe WNV infection in humans 
have been described, including older age, preexisting conditions 
such as diabetes or hypertension (48), and genetic predisposition, 
with the same deletion of the CCR5 gene that protects from HIV 
infection being associated with severe WNV infection (49). Inter-
estingly, the present study revealed lower Treg frequencies in symp-
tomatic WNV+ donors even after the contraction phase 1 year after 
index donation. If the Treg frequency 1 year after index donation 
is used as a surrogate for the preinfection Treg baseline level, the 
asymptomatic subjects may have had a higher “Treg tone” prior 
to infection, with higher preinfection Treg frequencies associated 
with protection from symptomatic disease. Alternatively, asymp-
tomatic and symptomatic populations may have had similar Treg 
frequencies prior to infection, but in the first 2 weeks of infection 
(prior to the first Treg measurement) those with asymptomatic 
infection had a more robust early Treg expansion.
As a preinfection sample was not available in our donor popu-
lation, we utilized a well-characterized mouse model of WNV 
Figure 5
Age does not confound the relation-
ship between Treg frequency and 
symptomatic WNV infection. (A) Sub-
ject age within the 18 asymptomatic, 
14 symptomatic donors; horizontal 
bars represent mean age. (B) Treg 
frequencies vs. age of 30 WNV+ 
donors at 30 days after index dona-
tion. Correlation coefficient = 0.187.
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infection that in many respects resembles the human disease. 
Unlike in humans, Treg levels did not increase in mice that sur-
vived WNV infection and actually fell in mice that died. Although 
further study is warranted, one possible explanation for this dif-
ference is that mice are more susceptible than humans to WNV 
and experience symptoms quickly after infection, dying around 
day 10 to day 14 after infection. Humans are less susceptible to 
WNV, and symptoms, if they develop, seem to persist for a lon-
ger duration, suggesting a slower viral clearance or protracted 
inflammation. In support of the human data, we observed lower 
Treg frequencies in symptomatic animals, though this difference 
did not attain statistical significance at the preinfection time 
point. Experiments with Foxp3DTR mice (50) showed an acceler-
ated fatal infection with WNV after Treg ablation, establishing 
a protective role of Tregs in WNV acute infection. As an inverse 
correlation between the level of Tregs and the level of WNV-spe-
cific CD8+ T cells was observed in mice, we speculate that Tregs 
may exert a protective effect by dampening the WNV-specific 
immune response and inflammation.
While the current study was built on a unique set of donor speci-
mens, some limitations were inherent in its design. Symptom ques-
tionnaires only covered the week before and 2 weeks after index 
donation, limiting study of long-term effects of WNV infection. 
Additionally, analysis of peripheral blood may not fully reflect 
the situation at sites of infection, and lower peripheral Treg levels 
may not correlate with tissue levels (39, 46, 47). Furthermore, this 
study was drawn from a population of healthy donors who did 
not develop severe, neurological disease. Finally, the correlation 
between Tregs and disease outcome may not be sustained in sub-
jects with neuroinvasive WNV infection, since high Treg levels, in 
theory, could impair viral clearance from infected neurons. Against 
this, however, experiments in mice indicate a net protective role for 
Tregs during WNV infection.
Figure 6
Lower frequency of Tregs in symptomatic WNV-infected mice. (A) 
Percentage change in body weight for 8 hunched mice versus 12 non-
hunched mice 8 days after infection; horizontal bars represent mean. 
(B) Correlation between the percentage change in body weight and 
the amount of WNV in the brain from 20 mice at day 8 after infection. 
Correlation coefficient = 0.65. Plaque assay results for viral burden 
in spinal cord (C) or brain (D) tissues collected from 12 asymptom-
atic and 8 symptomatic mice from a group of 20 mice sacrificed at 
day 8 after infection; horizontal bars represent mean. (E) Percentage 
survival for 40 mice over 28 days after infection. (F) Treg-gating strat-
egy in mouse experiments. PBMCs were stained ex vivo for surface 
TCRβ, CD4, CD25, and intracellular CD152 and Foxp3. Lymphocytes 
were gated and dead cells excluded if positive for the Aqua-amine 
dye. CD152+Foxp3+ Tregs were enumerated among CD4+TCRβ+ cells. 
(G) Treg frequencies in mice that survived to day 28 after infection 
(n = 17) and died prior to day 28 after infection (n = 18) are shown 
before infection and at 14 days after infection. Error bars represent 
SEM. (H) Association between high Treg frequencies and low WNV-
specific CD8+ T cells in WT mice (n = 15) at 8 days after infection with 
1 PFU of WNV. Horizontal bars represent means. Samples were clas-
sified as “high” WNV-specific CD8+ T cells if the value was higher than 
the mean value for all the samples (3.1% of splenic T cells at day 8) 
and “low” if the value was lower than the mean. **P < 0.01.
Figure 7
Increased lethality following WNV infection in mice lacking Foxp3+ Tregs. (A) Fifteen untreated WNV-infected WT C57BL/6 mice (WT no DT), 15 
DT-treated WNV-infected WT mice (WT + DT), 11 untreated WNV-infected Foxp3DTR mice (Foxp3-DTR no DT), and 14 DT-treated WNV-infected 
Foxp3DTR mice (Foxp3-DTR + DT) were monitored for clinical scores and weight loss daily. DT treatment was given on day –1 and day 0. The 
designation for the clinical scores is as follows: 1, ruffled fur/hunched; 2, paresis/difficulty walking; 3, paralysis; 4, moribund; and 5, dead. After 
day 12, only 1 Foxp3-DTR (+DT) mouse survived. Error bars represent SEM. (B) The survival data are compiled from 4 independent experi-
ments. P value for WT vs. Foxp3-DTR (+DT) = 0.0086; Bonferroni corrected = 0.026.
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The behavior of natural Tregs in humans has been described 
primarily for tuberculosis and chronic viral infections (51–53). 
In HCV infection, another Flaviviridae family member, an inverse 
correlation between Treg number in the periphery of liver biop-
sies and the histological inflammatory score was reported (54). 
People chronically infected with HCV have more circulating Tregs 
in peripheral blood than uninfected people or those who resolve 
HCV infection (55). Interestingly, a decrease in Treg number 
or function was found in the peripheral blood of symptomatic 
patients infected with HIV (56) or HCV (57), but Treg levels in 
acute HCV infection do not predict the ability to clear viremia 
(58). Tregs have also been studied in dengue virus infection (a 
Flavivirus that causes acute but not chronic infection), in which 
Treg expansion but not the absolute level of Tregs was lower in 
children with severe disease (47). While numerous studies have 
shown Treg changes in disease states, none have correlated disease 
outcome with a difference in Treg frequency.
We also explored potential factors that would differentially 
affect Treg frequencies in the asymptomatic and symptomatic 
donors. Previous studies reported higher frequencies of Tregs in 
elderly subjects (37), but age did not correlate with symptomatic 
status or Treg level in our study cohort. We also examined the 
general level of immune activation in asymptomatic and symp-
tomatic donors. Asymptomatic donors with higher Treg levels 
did not possess significantly lower magnitude WNV-specific T 
cell responses, although there was a trend to more asymptomat-
ic donors having undetectable effector T cell responses, whereas 
mice with higher Treg levels had a lower number of WNV-spe-
cific CD8+ T cells. Finally, no difference between asymptomatic 
and symptomatic WNV+ donors was found in their antibody 
responses or in the accumulation of selected systemic chemo-
kines and cytokines in serum. Future studies will be required to 
determine the contribution of innate immunity and the mecha-
nisms of induction and action of Tregs, specifically, how they 
ameliorate clinical outcome after WNV infection. In summary, 
levels of Tregs appear to predict WNV disease outcome, with 
higher Treg frequencies in the early phases of infection pro-
tecting from symptomatic infection. Although a CD8+ T cell 
response is required to clear WNV infection (36), an excessive 
response may cause immunopathology (13). Thus, the down-
regulation of an effective response by Tregs may be critical for 
mitigating bystander injury and disease pathology in the CNS. 
A better understanding of the dynamics, distribution, and func-
tion of Tregs may provide new avenues for pharmacologic con-
trol of viral pathogenesis.
Methods
Study design and subjects. From over 800,000 United Blood Services dona-
tions screened for WNV in 2005, 45 were confirmed positive for WNV 
RNA at index donation and reactive on a follow-up sample for anti-WNV 
IgM antibodies. Of the 35 WNV+ donors willing to participate after 
informed consent under UCSF Institutional Review Board approval, 
symptom questionnaires were successfully completed for the 32 subjects 
included in the current study. Samples were collected at regional blood 
centers and shipped via courier to the Blood Systems Research Institute. 
First PBMC samples were received a mean of 15 days after index dona-
tion, with follow-up samples extending to 1 year. Questionnaires cover-
ing 12 possible WNV-related symptoms (fever, headache, eye pain, body 
aches, new skin rash, swollen lymph nodes, nausea or vomiting, muscle 
weakness, confusion, disorientation, memory problems, or other) were 
administered at study enrollment and 2 weeks after enrollment. Sam-
ples were also drawn from 17 age-matched healthy uninfected negative 
control subjects (mean age = 42.2 years for WNV–; 47.4 years for WNV+; 
P = 0.12). All WNV+ blood donors enrolled in this study tested negative 
for other blood-borne pathogens, including HIV, HCV, HBV, human T 
cell lymphotropic virus (HTLV), and syphilis.
WNV RNA and antibody detection. WNV RNA was detected using a Tran-
scription-Mediated Amplification assay (Gen-Probe). Plasma specimens 
were tested for WNV IgM and IgG using ELISA kits (Focus Diagnostics). 
An IgG sample-to-calibrator ratio (SCR) of greater than 1.5 and an IgM 
SCR of greater than 1.1 were considered positive. Time windows of 10 days 
were selected for assessment of WNV antibody persistence. Multiple results 
available for a given donor within a given time window were averaged.
Virus. The lineage I WNV strain (3000.0259) isolated in New York in 
2000 (WNV-NY) was propagated once in C6/36 Aedes albopictus cells and 
used for in vivo experiments. For survival comparisons between WT and 
Foxp3DTR C57BL/6 mice, the WNV strain TX 2002-HC was used as previ-
ously described (5).
Animal experiments. Mice were bred under pathogen-free conditions. 
Eight- to twelve-week-old WT of congenic Foxp3DTR C57BL/6 mice were 
inoculated subcutaneously with WNV via the footpad. Diphtheria toxin 
was administered intraperitoneally (50 μg/kg) at day –1 and (30 μg/kg) at 
day 0. Mice were genotyped and bred in the animal facilities of the Wash-
ington University School of Medicine, and experiments were performed 
with approval of the Washington University Animal Studies Committee.
Isolation of PBMC and T cell subpopulations: human samples. Plasma was col-
lected after centrifugation, and PBMCs were isolated on a Ficoll-Paque 
PLUS density gradient (GE Healthcare Life Sciences). Aliquots of 10 × 106 
cells were frozen in medium containing 90% FBS (HyClone) and 10% DMSO 
(Fisher BioReagents) and stored in liquid nitrogen. CD4+CD25+ cells were 
positively isolated with magnetic beads using a human CD4+CD25+ Reg-
ulatory T Cell Isolation Kit (Miltenyi Biotec). The average purity of the 
CD4+CD25+ fraction was 86% (3 independent experiments) after a nega-
tive-selection enrichment step for CD4+ T cells followed by a second-step 
positive selection for CD25+ cells and negative selection for CD25– cells.
Isolation of PBMC and T cell subpopulations: mouse samples. Blood was col-
lected preinfection and on day 8, 14, or 28 after infection. PBMCs were 
isolated by Percoll gradient centrifugation, washed, and frozen in RPMI 
1640, 40% FBS, and 10% DMSO prior to characterization.
RT-PCR. mRNA was isolated from CD4+CD25+ or CD4+CD25– T cell sub-
sets using an RNeasy Mini Kit (QIAGEN). Analysis of Foxp3 gene expression 
by RT-PCR was performed using a QIAGEN OneStep RT-PCR Kit. Primers 
used for RT-PCR were as follows: β-actin, forward: 5′-AGCCTCGCCTTT-
GCCGA-3′ and reverse: 5′-CTGGTGCCTGGGGCG-3′; Foxp3, forward: 
5′-CACTGGGGTCTTCTCCCTC-3′ and reverse: 5′-TGTGCAGACTCAG-
GTTGTGG-3′ (Operon Biotechnologies Inc.).
Figure 8
Similar systemic effector immune responses in symptomatic and 
asymptomatic human WNV infection. WNV-specific T cell responses 
during the first 60 days after index donation. Comprehensive analy-
sis of WNV-specific T cell responses by anti–IFN-γ ELISPOT assay 
revealed (A) the median peak number of recognized WNV peptides 
and (B) the median peak magnitude of responses over 3 time points 
in the first 60 days after index donation for 18 asymptomatic and 14 
symptomatic WNV+ donors. Horizontal bars represent median quanti-
ties. (C) IgM and IgG response over the 90 days after index donation 
in 18 asymptomatic and 14 symptomatic WNV+ donors; means with 
SEM bars are displayed. (D) Cytokine profiles after index donation. 
Results are shown for analysis of plasma from 11 asymptomatic and 
8 symptomatic WNV+ donors spanning the year after index donation. 
Medians with SEM bars are displayed.
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Flow cytometry: human samples. PBMCs were incubated with ethidium 
monoazide for live cell gating. Stains included anti-CD14–TriColor, anti-
CD16–PECy5, anti-CD19–PECy5, anti-CD4–Alexa Fluor 700, anti-CD127–
PE, and anti-CD25–PECy7 (surface); anti-CD3–Pacific Blue, anti-CD152–
allophycocyanin (APC), and anti-Foxp3–FITC (intracellular).
Flow cytometry: mouse samples. PBMCs were stained with LIVE/DEAD 
Aqua-amine (Invitrogen). Stains included anti-TCRβ–PECy5, anti-CD4–
Alexa Fluor 700, and anti-CD25–APC (surface); and anti-CD152–PE and 
anti-Foxp3–PECy7 (intracellular).
Treg functional assays. CD4+CD25+ T cells (30 × 103) and the indicated ratio 
of CD4+CD25– T cells labeled with 5 μM CFSE (Invitrogen) were cultured 
for 4 days at 37°C and 5% CO2 in duplicate wells in 96-well round-bottom 
plates (Corning Costar) with or without 2.5 μg/ml anti-CD3 and anti-CD28 
(BD Biosciences). After 96 hours, cells were stained with propidium iodide, 
anti-CD3–Pacific Blue, anti-CD4–Alexa Fluor 700, and anti-CD25–PECy7 
(clone: MA-251) and were analyzed for CFSE dilution by flow cytometry.
WNV-specific CD8+ T cells. For detection of WNV-specific mouse CD8+ T 
cells, splenocytes were restimulated ex vivo with a class I MHC Db-restricted 
immunodominant NS4B WNV peptide (59) and incubated with FITC-con-
jugated anti-CD8 (BD Biosciences) at 4°C for 30 minutes. Subsequently, 
cells were washed, fixed in 1% paraformaldehyde, permeabilized, and incu-
bated additionally with Alexa Fluor 488–conjugated anti–IFN-γ prior to 
analysis by flow cytometry.
ELISPOT assays. Peptides were divided into 93 pools of 8 to 10 peptides, with 
each peptide present in 2 pools. The pattern of responses to the pools identi-
fied candidate peptides, which were retested individually in duplicate. PBMCs 
were plated in 96-well MultiScreen-IP plates (Millipore) precoated with anti–
IFN-γ antibody (mAb1-D1K; Mabtech) at 2 μg/ml in PBS (UCSF Cell Culture 
Facility). Cells were added at 100,000/well in 100 μl RPMI (UCSF Cell Culture 
Facility) plus 10% human AB serum (Sigma-Aldrich), 11 mM glucose, 2 mM 
l-glutamine, 23 mM NaHCO3P, and 50 U penicillin-streptomycin (termed 
R10H). The final concentration of each peptide was 5 μg/ml. Duplicate nega-
tive control wells (cells plus medium) and a positive control well, 0.5 μg/ml 
phytohemagglutinin (PHA) (Sigma-Aldrich), were run on each plate. Plates 
were incubated 20 hours at 37°C and 5% CO2, then washed and incubated at 
25°C for 60 minutes with biotinylated anti–IFN-γ antibody (Mabtech). Plates 
were washed and incubated with streptavidin-alkaline phosphatase (Mabtech) 
for 60 minutes at 25°C. Plates were washed prior to addition of 5-bromo-4-
chloro-3-indolylphosphate and nitroblue tetrazolium substrates (Bio-Rad). 
Spots were counted, and results were expressed as SFCs/106 PBMCs after 
background subtraction. Responses in 5 WNV– healthy controls ranged from 
0 to 30 SFCs/106 PBMCs, with over 80% of wells showing no spots. Responses 
were counted as positive if they were 3 times above background of the plate 
and consisted of 50 or more SFCs/106 PBMCs.
Cytometric bead array analysis of plasma cytokines and chemokines. Plasma was 
available for 19 of the 32 panels described above and was analyzed by human 
Th1/Th2 cytokine, inflammation, and chemokine Cytometric Bead Array 
(CBA) kits (BD Biosciences) according to the manufacturer’s protocols (60). 
Residual plasma volume was insufficient for testing on the remaining 13 
subjects. Results were analyzed using BD CBA Analysis Software.
Mouse viral burden measurements. After extensive perfusion with PBS, 
organs were removed and homogenized; titers were determined by viral 
plaque assay on BHK21-15 cells as described (39).
Statistics. For Gaussian distributed data, statistical significance was evalu-
ated using a Student’s 2-tailed t test and, where appropriate, a 2-tailed, 
unpaired Student’s t test. Differences were considered significant if the 
P value was less than 0.05. For non-Gaussian distributed data (i.e., cytokine 
and chemokine measurements, viral burden data), the nonparametric Mann-
Whitney rank sum test for 2 independent populations was performed using 
GraphPad Prism software (GraphPad Software). For comparison of surviv-
al curves, the log-rank (Mantel-Cox) test with Bonferroni’s correction for 
multiple comparisons was performed using GraphPad Prism software. For 
comparison of multiple longitudinal measurements (e.g., Treg frequencies), 
the mean value at each time period was calculated using generalized estimat-
ing equation regression for panel data within groups of subjects defined by 
whether they had symptomatic or asymptomatic WNV infection using Stata 
9.0SE software (Stata Corp.). We used robust standard errors to account for 
multiple observations (serial bleed samples) from these individuals.
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